4Burton DR,Desrosiers RC,Doms RW,et al.Public health.A sound rationale needed for phase ill HI V-1 vaccine trials[ J ].Science,2004,303(5656):316
5Yang X,Farzan M,Wyatt R,et al.Characterization of stable,soluble trimers containing complete ectodomains of human immunodeficiency.Virus type 1 envelope glycoproteins[ J ].J Virol,2000,74 (12):5716-5725.
6Yang X,Lee J,Mahony EM,et al.Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin[J ].J Virol,2002,76(9):4634-4642.
7Sanders RW,Schiffner L,Master A,et al.Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits[J].J Virol.2000,74(11):5091-5100.
8Binley JM,Sanders RW,Clas B,et al.A recombinant human immunodeficiency virus type 1 envelope uycoprotein compiex stapilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure[J ].J Virol,2000,74 (2):627-643.
9Kang SM,Quan FS,Huang C,et al.Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies[ J ].Virology,2005,331 (1):20-32.
10Zolla-Pazner S.Identifying epitopes of HIV-1 that induce protective antibodies[ J ].Nat Rev Immunol,2004,4 (3):199-210.
